{
    "id": 25717,
    "fullName": "SLC44A4 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SLC44A4 positive indicates the presence of the SLC44A4 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 80736,
        "geneSymbol": "SLC44A4",
        "terms": [
            "SLC44A4",
            "C6orf29",
            "CTL4",
            "DFNA72",
            "hTPPT1",
            "NG22",
            "TPPT"
        ]
    },
    "variant": "positive",
    "createDate": "11/03/2016",
    "updateDate": "11/03/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9153,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ASG-5ME inhibited tumor growth in SLC44A4-expressing ovarian cancer cell line xenograft models (PMID: 27550944).",
            "molecularProfile": {
                "id": 26752,
                "profileName": "SLC44A4 positive"
            },
            "therapy": {
                "id": 4914,
                "therapyName": "ASG-5ME",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6935,
                    "pubMedId": 27550944,
                    "title": "The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550944"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12651,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ASG-5ME treatment resulted in one partial response and a disease control rate of 47% in patients with gastric adenocarcinoma expressing SLC44A4 (PMID: 26994014).",
            "molecularProfile": {
                "id": 26752,
                "profileName": "SLC44A4 positive"
            },
            "therapy": {
                "id": 4914,
                "therapyName": "ASG-5ME",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10536,
                    "pubMedId": 26994014,
                    "title": "A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26994014"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12650,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ASG-5ME treatment resulted in one partial response and a disease control rate of 33% in patients with pancreatic adenocarcinoma expressing SLC44A4 (PMID: 26994014).",
            "molecularProfile": {
                "id": 26752,
                "profileName": "SLC44A4 positive"
            },
            "therapy": {
                "id": 4914,
                "therapyName": "ASG-5ME",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10536,
                    "pubMedId": 26994014,
                    "title": "A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26994014"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9156,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of ASG-5ME and Abraxane (nab-paclitaxel) inhibited tumor growth in a SLC44A4-expressing patient-derived xenograft (PDX) model of pancreatic cancer, with increased efficacy compared to either agent alone (PMID: 27550944).",
            "molecularProfile": {
                "id": 26752,
                "profileName": "SLC44A4 positive"
            },
            "therapy": {
                "id": 4915,
                "therapyName": "ASG-5ME + Nab-paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6935,
                    "pubMedId": 27550944,
                    "title": "The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550944"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9154,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ASG-5ME inhibited tumor growth in SLC44A4-expressing pancreatic cancer patient-derived xenograft (PDX) models (PMID: 27550944).",
            "molecularProfile": {
                "id": 26752,
                "profileName": "SLC44A4 positive"
            },
            "therapy": {
                "id": 4914,
                "therapyName": "ASG-5ME",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6935,
                    "pubMedId": 27550944,
                    "title": "The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550944"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9155,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ASG-5ME inhibited tumor growth in prostate cancer cell line xenograft models and patient-derived xenograft (PDX) models expressing SLC44A4 (PMID: 27550944).",
            "molecularProfile": {
                "id": 26752,
                "profileName": "SLC44A4 positive"
            },
            "therapy": {
                "id": 4914,
                "therapyName": "ASG-5ME",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6935,
                    "pubMedId": 27550944,
                    "title": "The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550944"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9157,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of ASG-5ME and Abraxane (nab-paclitaxel) inhibited tumor growth in a SLC44A4-expressing patient-derived xenograft (PDX) model of prostate cancer, with increased efficacy compared to either agent alone (PMID: 27550944).",
            "molecularProfile": {
                "id": 26752,
                "profileName": "SLC44A4 positive"
            },
            "therapy": {
                "id": 4915,
                "therapyName": "ASG-5ME + Nab-paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6935,
                    "pubMedId": 27550944,
                    "title": "The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550944"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9152,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ASG-5ME inhibited tumor growth in colon cancer cell line xenograft and patient-derived xenograft (PDX) models (PMID: 27550944).",
            "molecularProfile": {
                "id": 26752,
                "profileName": "SLC44A4 positive"
            },
            "therapy": {
                "id": 4914,
                "therapyName": "ASG-5ME",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6935,
                    "pubMedId": 27550944,
                    "title": "The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550944"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26752,
            "profileName": "SLC44A4 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}